PreScience Labs

Publications

  1. Chapiro J, Sur S, Savic LJ, Ganapathy–Kaniappan S, Reyes J, Duran R, Chettiar–Thiruganasambandam S, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. (2014). Systemic Delivery of Microencapsulated 3–Bromopyruvate for the Therapy of Pancreatic Cancer. Clin Cancer Res. 2014 Oct 17. pii: clincanres.1271.2014. [Epub ahead of print]
  2. Kunjithapatham, R., Geschwind, JF., Rao, PP., Boronina, TN., Cole, RN and Ganapathy–Kanniappan, S. (2013). Systemic administration of 3–bromopyruvate reveals its interaction with serum proteins in a rat model. BMC Res Notes (in press).
  3. Ota S, Geschwind JF, Buijs M, Wijlemans JW, Kwak BK, Ganapathy–Kanniappan S. Ultrasound–guided direct delivery of 3–bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Target Oncol. 2013 Mar 26. [Epub ahead of print] PubMed PMID: 23529644.
  4. Buijs M, Wijlemans JW, Kwak BK, Ota S, Geschwind JF. Antiglycolytic Therapy Combined with an Image–guided Minimally Invasive Delivery Strategy for the Treatment of Breast Cancer. J Vasc Interv Radiol. 2013 May;24(5):737–43. doi: 10.1016/j.jvir.2013.01.013. Epub 2013 Mar 13. PubMed PMID: 23489770.
  5. Ganapathy–Kanniappan S, Kunjithapatham R, Geschwind JF. Anticancer efficacy of the metabolic blocker 3–bromopyruvate: specific molecular targeting. Anticancer Res. 2013 Jan;33(1):13–20. PubMed PMID: 23267123.
  6. Ganapathy–Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA, Buijs M, Vali M, Geschwind JF. Human hepatocellular carcinoma in a mouse model:assessment of tumor response to percutaneous ablation by using glyceraldehyde–3–phosphate dehydrogenase antagonists. Radiology. 2012 Mar;262(3):834–45. doi: 10.1148/radiol.11111569. PubMed PMID: 22357885; PubMed Central PMCID: PMC3285229.
  7. Schaefer NG, Geschwind JF, Engles J, Buchanan JW, Wahl RL. Systemic administration of 3–bromopyruvate in treating disseminated aggressive lymphoma. Transl Res. 2012 Jan;159(1):51–7. doi: 10.1016/j.trsl.2011.08.008. Epub 2011 Sep 22. PubMed PMID: 22153810.
  8. Liapi E, Geschwind JF, Vali M, Khwaja AA, Prieto–Ventura V, Buijs M, Vossen JA, Ganapathy S, Wahl RL. Assessment of tumoricidal efficacy and response to treatment with 18F–FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3–bromopyruvate in the VX2 model of liver tumor. J Nucl Med. 2011 Feb;52(2):225–30. doi: 10.2967/jnumed.110.083162. Epub 2011 Jan 13. Erratum in: J Nucl Med. 2011 Mar;52(3):495. PubMed PMID: 21233194.
  9. Ganapathy–Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Geschwind JF. 3–bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010 Aug;11(5):510–7. Review. PubMed PMID: 20420565.
  10. Ganapathy–Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Vali M. 3–Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res. 2010 Mar;30(3):923–35. PubMed PMID: 20393016.
  11. Ganapathy–Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Vali M. The pyruvic acid analog 3–bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. Assay Drug Dev Technol. 2010 Apr;8(2):258–62. doi: 10.1089/adt.2009.0226. PubMed PMID: 20085459.
  12. Ganapathy–Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, Vali M. Glyceraldehyde–3–phosphate dehydrogenase (GAPDH) is pyruvylated during 3–bromopyruvate mediated cancer cell death. Anticancer Res. 2009 Dec;29(12):4909–18. PubMed PMID: 20044597.
  13. Liapi E, Geschwind JF. Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via aloco–regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):405–6. doi: 10.1007/s00534–009–0236–x. Epub 2009 Nov Review. PubMed PMID: 19890602; PubMed Central PMCID: PMC3063000.
  14. Vossen JA, Buijs M, Syed L, Kutiyanwala F, Kutiyanwala M, Geschwind JF, Vali M. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra–arterial treatment with 3–bromopyruvate and chemoembolization. Clin Exp Metastasis.2008;25(7):811–7. doi: 10.1007/s10585–008–9195–x. Epub 2008 Jul 23. PubMed PMID: 18649116.
  15. Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha–Ngwodo O, Shanmugasundaram G, Syed L, Wahl RL, Geschwind JF. Targeting of VX2 rabbit liver tumor by selective delivery of 3–bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther. 2008 Oct;327(1):32–7.doi: 10.1124/jpet.108.141093. Epub 2008 Jun 30. PubMed PMID: 18591216; PubMed Central PMCID: PMC2760588.
  16. Buijs M, Vossen JA, Geschwind JF, Ishimori T, Engles JM, Acha-Ngwodo O, Wahl RL, Vali M. Specificity of the anti–glycolytic activity of 3–bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs. 2009Apr;27(2):120–3. doi: 10.1007/s10637–008–9145–0. Epub 2008 Jun 14. PubMed PMID:18553054.
  17. Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C,Geschwind JF. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3–bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol. 2007 Jan;18(1Pt 1):95–101. PubMed PMID: 17296709.
  18. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2004 Jun;4(3):449–57. Review. PubMed PMID:15161443.
  19. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta. 2002 Sep 10;1555(1–3):14–20. PubMed PMID: 12206885.
  20. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 2002 Jul 15;62(14):3909–13. PubMed PMID: 12124317.
  21. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett.2001 Nov 8;173(1):83–91. PubMed PMID: 11578813.
  22. Chapiro J, Sur S, Savic LJ, Ganapathy-Kaniappan S, Reyes J, Duran R, Chettiar-Thiruganasambandam S, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. (2014). Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clin Cancer Res. 2014 Oct 17. pii: clincanres.1271.2014. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25326230